



NEW TREATMENT FOR DRY AMD

We now have a treatment option for patients losing vision from Dry AMD. Overactive inflammation, and specifically, high levels of complement in the retina lead to photoreceptor (rods and cones) loss and atrophy formation. Complement inhibition appears to slow the process down and the FDA recently approved pegcetacoplan based on results of two large trials that demonstrated the drug significantly slows the progression of geographic atrophy.

Results are not miraculous, but they are significant and the effect appears to build over time. So, we believe this could make a big difference for many patients over the long term.

However, it has its downsides: the drug must be injected every 1-2 months, and there is some risk of conversion to wet AMD. As well as risks always associated with intraocular injection such as infection.

Therefore, this will not be something we recommend for everyone but will focus, at least at first, on those that are at high risk of progression.

High Risk for Worsening Dry AMD

Vision loss from AMD
Prior documented worsening
Geographic atrophy in the other eye

What we should do

- Discuss your eye conditions with your primary eye care provider.
- If you have Dry AMD and would like to consider treatment, give us a call.



ASSOCIATED VITREORETINAL
AND UVEITIS

CONSULTANTS
F. RYAN PRALL, M.D.